Efficacy of High-Intensity Laser Therapy in Early-Stage Symptomatic Knee Osteoarthritis (HILT-ESCOA)

October 5, 2026 updated by: Prof. Dr. Simin Hepgüler, Ege University

Efficacy of High-Intensity Laser Therapy in Early-Stage Symptomatic Knee Osteoarthritis: A Randomized Controlled Trial

This randomized, double-blind, sham-controlled clinical trial evaluated the effectiveness of high-intensity laser therapy (HILT) in patients with early-stage symptomatic knee osteoarthritis.

A total of 39 participants were randomly assigned to receive either HILT combined with a standardized home exercise program or sham laser therapy combined with the same exercise program. Laser or sham treatment was administered over 10 weekday sessions during a two-week period.

Participants were assessed at baseline, immediately after treatment, and at the three-month follow-up. Assessments included pain intensity, physical function, health-related quality of life, walking performance, knee range of motion, and muscle strength.

The aim was to determine whether adding HILT to exercise provides additional clinical benefits compared with sham laser therapy combined with exercise.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

39

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • İzmir
      • Izmir, İzmir, Turkey (Türkiye), 35100
        • Ege University Faculty of Medicine Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Inclusion Criteria:

    1. Patients presenting to the Physical Medicine and Rehabilitation outpatient clinics of Ege University Faculty of Medicine Hospital with knee pain lasting no longer than 6 months and a Visual Analog Scale (VAS) pain score of at least 4.
    2. Availability of bilateral weight-bearing knee radiographs in two views obtained within the preceding 6 months.
    3. Diagnosis of early symptomatic knee osteoarthritis according to the Italian Society of Rheumatology International Initiative (ESKOA) criteria.
    4. Ability to cooperate with the prescribed exercise program.
    5. Willingness to participate in the study and provision of informed consent.
    6. Age eligibility:
  • 40-49 years: Presence of at least one of the following risk factors for early symptomatic knee osteoarthritis.

  • 50-75 years: Eligible regardless of the presence of the listed risk factors.

Risk factors:

  • Body mass index (BMI) greater than 25 kg/m².
  • Family history of knee osteoarthritis.
  • Previous knee injury.
  • Lower-limb alignment abnormality.
  • Lower-limb length discrepancy.
  • Osteoarthritis at other anatomical sites.
  • Metabolic syndrome.
  • Difficulty initiating brisk walking or running after a period of inactivity.

Exclusion Criteria:

  1. Receipt of an intra-articular knee injection or physical therapy within the preceding 6 months, or use of natural health products such as glucosamine or chondroitin.

  2. History of knee surgery.

  3. Presence of inflammatory arthritis, including rheumatoid arthritis, psoriatic arthritis, or gouty arthritis.

  4. History of trauma within the preceding 6 months.

  5. Fixed knee flexion deformity greater than 10 degrees or varus/valgus deformity greater than 15 degrees.

  6. Referred pain originating from the lumbar spine or hip.

  7. Neurological deficits affecting the lower extremities.

  8. Medical conditions that could prevent participation in the exercise program or completion of the study, including:

    • Myocardial infarction or cerebrovascular event within the preceding 3 months.
    • Congestive heart failure.
    • Severe chronic obstructive pulmonary disease.
    • History of myocardial ischemia during treadmill testing.
    • History of arterial or venous circulatory disorders.
  9. Presence of a cardiac pacemaker or metal implants.

  10. Pregnancy.

  11. History of malignancy, knee osteonecrosis, infectious disease, psychiatric illness, or bleeding diathesis.

  12. Epilepsy.

  13. Conditions impairing cooperation or communication, including language barriers, aphasia, marked affective disorders, or a history of severe psychiatric illness.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: HILT + Exercise

Participants received high-intensity laser therapy (HILT) combined with a standardized home exercise program. HILT was administered in 10 sessions over two consecutive weeks (five sessions per week). Participants also performed the prescribed home exercise program throughout the treatment period.

High-intensity laser therapy (HILT) was administered using a 1064-nm laser at a frequency of 20 Hz, with an energy density of 1530 mJ/cm² and a total energy of 3000 J per session. Treatment consisted of 10 sessions administered on consecutive weekdays over a two-week period. HILT was combined with a standardized home exercise program.

Both groups received the same standardized home exercise program, including knee range-of-motion exercises (3 sets of 10-12 repetitions), static stretching exercises (3 repetitions with a 30-second hold), and isometric and isotonic strengthening exercises (3 sets of 10-12 repetitions). The exercise program was prescribed as a home-based intervention alongside the assigned laser or sham laser treatment.

Sham Comparator: Sham Laser + Exercise

Participants received sham laser therapy combined with the same standardized home exercise program as the experimental group. The sham procedure was administered without therapeutic laser energy in 10 sessions over two consecutive weeks (five sessions per week).

Both groups received the same standardized home exercise program, including knee range-of-motion exercises (3 sets of 10-12 repetitions), static stretching exercises (3 repetitions with a 30-second hold), and isometric and isotonic strengthening exercises (3 sets of 10-12 repetitions). The exercise program was prescribed as a home-based intervention alongside the assigned laser or sham laser treatment.

Sham laser therapy was administered using the same treatment schedule and application procedure as the active HILT group, but without delivering therapeutic laser energy. Participants received 10 sham sessions over two consecutive weeks (five sessions per week), combined with the same standardized home exercise program.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain Intensity Assessed by Visual Analog Scale (VAS)
Time Frame: Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Pain intensity was assessed using a 10-cm Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline
Knee Symptoms and Physical Function Assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Time Frame: Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Knee osteoarthritis-related symptoms and physical function were assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), including pain, stiffness, and physical function subscales. Higher scores indicate greater symptom severity and functional impairment.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Functional Status Assessed by Health Assessment Questionnaire (HAQ)
Time Frame: Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Functional status and activities of daily living were assessed using the Health Assessment Questionnaire Disability Index (HAQ-DI). Scores range from 0 to 3, with higher scores indicating greater disability and poorer functional status.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline
Health-Related Quality of Life Assessed by Short Form Health Survey (SF-12) Physical Component Summary (PCS)
Time Frame: Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Physical health-related quality of life was assessed using the Physical Component Summary (PCS) score of the 12-Item Short Form Health Survey (SF-12). Higher scores indicate better physical health-related quality of life.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline
Health-Related Quality of Life Assessed by Short Form Health Survey (SF-12) Mental Component Summary (MCS)
Time Frame: Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Mental health-related quality of life was assessed using the Mental Component Summary (MCS) score of the 12-Item Short Form Health Survey (SF-12). Higher scores indicate better mental health-related quality of life.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Functional Exercise Capacity Assessed by 6-Minute Walk Test (6MWT)
Time Frame: Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Functional exercise capacity was assessed using the 6-Minute Walk Test (6MWT). The total distance walked during 6 minutes was recorded in meters. A greater walking distance indicates better functional exercise capacity.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline
Knee Range of Motion (ROM)
Time Frame: Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Knee range of motion was assessed using a goniometer. Active and passive knee range of motion were measured in degrees.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline
Lower Extremity Muscle Strength Assessed by Manual Muscle Testing (MMT)
Time Frame: Baseline, immediately after the 2-week treatment period, and 3 months after baseline

Lower extremity muscle strength was assessed using manual muscle testing (MMT). Muscle strength was graded on a 0-to-5 scale, with higher scores indicating greater muscle strength.

Baseline, immediately after the 2-week treatment period, and 3 months after baseline
Paracetamol Use
Time Frame: Throughout the study period, from baseline to the 3-month follow-up

Paracetamol use was monitored using a patient diary to assess analgesic use during the study. Changes in paracetamol use were evaluated as an additional indicator of treatment effectiveness.

Throughout the study period, from baseline to the 3-month follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: A.Simin Hepgüler, MD, Ege University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 5, 2025

Primary Completion (Actual)

January 18, 2026

Study Completion (Actual)

January 18, 2026

Study Registration Dates

First Submitted

September 30, 2026

First Submitted That Met QC Criteria

September 30, 2026

First Posted (Actual)

October 6, 2026

Study Record Updates

Last Update Posted (Actual)

October 8, 2026

Last Update Submitted That Met QC Criteria

October 5, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • EGE-PMR-HILT-2025-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified individual participant data may be made available from the corresponding author upon reasonable request, subject to ethical and institutional approval.

IPD Sharing Time Frame

De-identified individual participant data will be available upon reasonable request following publication of the manuscript.

IPD Sharing Access Criteria

De-identified individual participant data may be shared with qualified researchers upon reasonable request to the corresponding author (silaolmez@yahoo.com.tr), subject to ethical and institutional approval.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.